CIK 1776382
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 53.29% | 5 |
| Unclassified | 46.71% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | PHVS | PHARVARIS N V | Unclassified | 46.71% |
| 2 | ALMS | ALUMIS INC. | Health Care | 35.56% |
| 3 | ALXO | ALX ONCOLOGY HOLDINGS INC | Health Care | 9.21% |
| 4 | HRMY | Harmony Biosciences Holdings, Inc. | Health Care | 4.88% |
| 5 | LYEL | Lyell Immunopharma, Inc. | Health Care | 2.41% |
| 6 | ARTV | Artiva Biotherapeutics, Inc. | Health Care | 1.22% |
5/6 names classified · sector 53.3% of weight · industry 53.3% · mkt cap 53.3%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 53.3% of the book is sector-classified (unclassified names shown, never dropped).
Only 5% of book weight classified — the grid is NOT representative of the whole book.
Classified: 4.9% of book weight (1/6 names) · unclassified 95.1%: PHVS, ALMS, ALXO, LYEL, ARTV. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | PHVSPHARVARIS N V | 4,639,304 | $131M | 46.7% | HOLD |
| 2 | ALMSALUMIS INC | 4,528,408 | $100M | 35.6% | HOLD |
| 3 | ALXOALX ONCOLOGY HLDGS INC | 12,884,638 | $26M | 9.2% | ADD 33% |
| 4 | HRMYHARMONY BIOSCIENCES HLDGS IN | 489,194 | $14M | 4.9% | HOLD |
| 5 | LYELLYELL IMMUNOPHARMA INC | 337,697 | $7M | 2.4% | HOLD |
| 6 | ARTVARTIVA BIOTHERAPEUTICS INC | 531,337 | $3M | 1.2% | TRIM −18% |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| PHVSPHARVARIS N V | 4.3M | 4.3M | 4.3M | 4.6M | 4.6M | 4.6M | $131M |
| ALMSALUMIS INC | 2.8M | 2.8M | 4.6M | 4.6M | 4.6M | 4.5M | $100M |
| ALXOALX ONCOLOGY HLDGS INC | 9.7M | 9.7M | 9.7M | 9.7M | 9.7M | 12.9M | $26M |
| HRMYHARMONY BIOSCIENCES HLDGS IN | 539K | 489K | 489K | 489K | 489K | 489K | $14M |
| LYELLYELL IMMUNOPHARMA INC | — | — | 473K | 473K | 338K | 338K | $7M |
| ARTVARTIVA BIOTHERAPEUTICS INC | 1.5M | 1.2M | 1.1M | 1.1M | 649K | 531K | $3M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
